MIRM — Mirum Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1759425 ·
Last close
$89.70
Market Cap
$5.82B
52W High
$130.00
52W Low
$63.23
ADV30
614,130
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 176,243,000 145,895,000 -26,102,000 -67,227,000 1,044,981,000 330,728,000 1,055,403,000
Mar 2026 159,882,000 131,077,000 -63,163,000 -790,155,000 890,916,000 324,907,000 648,422,000
Dec 2025 148,932,000 120,668,000 -4,567,000 -5,730,000 842,813,000 296,683,000 528,123,000
Sep 2025 133,010,000 107,473,000 2,603,000 2,905,000 785,115,000 282,021,000 493,069,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-227,267,000
Investing CF
$-172,781,000
Financing CF
$506,612,000
CapEx
$-36,474,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-14.55
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,524,926,000
Inventory
$25,769,000
Receivables
$145,360,000
ST Investments
$107,563,000
EBIT TTM
$-844,100,000
Pretax Income TTM
$-857,538,000
Interest Exp TTM
$13,438,000
Analysts
14

Yahoo Snapshot (yfinance, live)

Total Revenue
$618,067,008
EBITDA
$-70,283,000
Free Cash Flow
$76,618,128
Enterprise Value
$6,702,299,136
Total Cash
$438,291,008
Total Debt
$762,948,992
Shares Out
64,932,203
Trailing EPS
$-14.08
Book Value
$-0.16
ROE
-703.0%
ROA
-6.8%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 521,312,000 -22,136,000 -23,363,000 842,813,000 528,123,000 314,690,000 55,827,000
Dec 2024 336,888,000 -87,606,000 -87,942,000 670,754,000 445,114,000 225,640,000 10,325,000
Dec 2023 186,374,000 -109,154,000 -163,415,000 646,621,000 397,951,000 248,670,000 -70,944,000
Dec 2022 77,062,000 -131,220,000 -135,665,000 352,906,000 210,869,000 142,037,000 -120,136,000

TTM Snapshot

Revenues TTM
$249,687,000
NetIncome TTM
$-52,500,000
OpCashFlow TTM
$0
Assets (Latest)
$842,813,000
Forward EPS
$-0.35

Max Pain — expiry 2026-12-18

max pain strike: $85.00 · spot: $85.39 · call oi: 1,188 · put oi: 472

Peers — same industry

TickerNameMarket CapLastDaily %
LGND LIGAND PHARMACEUTICALS INC $6.01B $301.52 —
COGT Cogent Biosciences, Inc. $5.61B $32.31 —
TVTX Travere Therapeutics, Inc. $5.60B $59.44 —
ORKA Oruka Therapeutics, Inc. $5.59B $84.46 —
LQDA Liquidia Corp $6.13B $68.43 —

News headlines (Yahoo Finance, 1h cache)

Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment
2026-09-28 12:38 · Yahoo
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
2026-09-28 12:00 · Yahoo
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
2026-09-27 21:00 · Yahoo
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
2026-09-25 23:00 · Yahoo
INCY, MIRM Slip Into FDA’s Weekend Decision Date On Shared Rare-Disease Pill
2026-09-25 18:43 · Yahoo
FDA Decision Watch: MRK, MIRM, INCY, GRAL Face Key Regulatory Catalysts This Week
2026-09-21 11:06 · Yahoo
MIRM, INCY Stocks In Focus — Will A September 26 FDA Ruling Reward This Week’s Gains?
2026-09-17 22:44 · Yahoo
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-14 20:01 · Yahoo
Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer
2026-09-08 12:30 · Yahoo
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-09-02 20:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.